At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 385 enrolled
Drug / intervention
Meningococcal vaccine GSK134612biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study to Assess Immunogenicity, Reactogenicity and Safety of Primary Vaccination With GSK Biologicals' MenACWY Vaccine (GSK134612) Given as 1 or 2 Doses to Healthy Toddlers 9-12 Months of Age
In Brief
A Phase 2 clinical trial evaluating Meningococcal vaccine GSK134612 for Infections, Meningococcal. Completed, enrolled 385 participants across 19 sites.
Detailed Summary
The purpose of the study is to characterize the safety and immunogenicity of 1 dose of GSK134612 vaccine at 12 months of age and of GSK134612 vaccine administered as 2 doses at 9 and 12 months of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Meningococcal
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2007
Enrollment StartJul 2007
Primary CompletionOct 2008
Study CompletionNov 2008
TodayJul 2026
First PostedMay 9, 2007
Enrollment StartJul 5, 2007
Primary CompletionOct 23, 2008
Study CompletionNov 26, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.1 years ago
Interventions
Meningococcal vaccine GSK134612biological
One or 2 intramuscular injections.